Repurposing sertraline sensitizes non-small cell lung cancer cells to erlotinib by inducing autophagy

JCI insight

Volumn 3, Issue 11, 2018, Pages

  Jiang, Xingwu ^a   Lu, Weiqiang ^a   Shen, Xiaoyang ^a   Wang, Quan ^b   Lv, Jing ^a   Liu, Mingyao ^a,c   Cheng, Feixiong ^d,e   Zhao, Zhongming ^b,f,g   Pang, Xiufeng ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e NORTHEASTERN UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS   (United States)

^g VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

Autophagy; Lung cancer; Oncology; Therapeutics

Indexed keywords

ADENYLATE KINASE; ANTINEOPLASTIC AGENT; ERLOTINIB; MTOR PROTEIN, HUMAN; SERTRALINE; TARGET OF RAPAMYCIN KINASE;

ANIMAL; AUTOPHAGY; CELL SURVIVAL; DRUG EFFECT; DRUG POTENTIATION; DRUG REPOSITIONING; DRUG RESISTANCE; DRUG SCREENING; HUMAN; LUNG TUMOR; MALE; METABOLISM; MORTALITY; MOUSE; NON SMALL CELL LUNG CANCER; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELL LINE;

ADENYLATE KINASE; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL SURVIVAL; DRUG REPOSITIONING; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ERLOTINIB HYDROCHLORIDE; HUMANS; LUNG NEOPLASMS; MALE; MICE; SERTRALINE; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85060116782     PISSN: None     EISSN: 23793708     Source Type: Journal    
DOI: 10.1172/jci.insight.98921     Document Type: Article

References (0)